BIOLASE (BLTI) Announces FDA 510(K) Clearance of Its ezlase Diode Laser for Pain Therapy & Relief
More News related to BLTI
- BIOLASE Reports Third Quarter, Nine-Month Results
- Trading Radar for 11/05: Starbucks (SBUX), CBS Corp. (CBS), CVS (CVS), Toyota (TM), Thomson Reuters (TRI)
- BIOLASE Introduces the Diolase 10(TM) Diode Laser for Pain Management, Therapeutic Applications
- BIOLASE Announces Revolutionary Gum Disease Treatment
- BIOLASE Conference Call: 2009 Third Quarter and Nine-Month Results
More News related to Corporate News
- Verizon (VZ) Executive McAdam Buys 17K Shares
- Herbalife (HLF) CEO Enters Trading Plan Covering 732K Shares
BIOLASE Technology, Inc. (NASDAQ: BLTI) announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market its ezlase(TM) diode laser system for therapeutic applications including temporary pain relief. The cleared indications are broad to cover medical and dental.
The FDA has given clearance for the ezlase for the following indications: "The ezlase(TM) diode system emits energy in the near-infrared spectrum to provide topical heating for the purpose of elevating tissue temperature for a temporary relief of minor muscle and joint pain and stiffness, minor arthritis pain, or muscle spasm, minor sprains and strains, and minor muscular back pain; the temporary increase in local blood circulation; the temporary relaxation of muscle."
Click Here To Try StreetInsider's LIVE NEWS FEED for FREE for a limited time! http://www.streetinsider.com/premium_content.php
Related Categories
Corporate NewsFDA
Stocks Mentioned
-0.13Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
